<DOC>
	<DOCNO>NCT01269151</DOCNO>
	<brief_summary>Multifocal-electroretinoram ( ERG ) microperimetry objective criterion asses retinal function . No information besides visual acuity exist development retinal function course wet AMD therapy Lucentis . The aim study evaluate value multifocal-ERG microperimetry sensitive tool early predictor recurrence disease . The second goal evaluate neuroprotective effect adequate therapy retinal function use microperimetry multifocal-ERG course wet AMD .</brief_summary>
	<brief_title>Ranibizumab Short- Log-term Effects Retinal Function wAMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Male female patient 50 year age 2. wet agerelated macular degeneration ( AMD ) 3. available followup 12 month 4. write informed consent 5. visual acuity 0.1 good Systemic condition treatment 1. history evidence severe cardiac disease ( e.g. , NYHA functional class III IV ) 2. clinical medical history unstable angina , acute coronary syndrome , myocardial infarction revascularization within last 6 month 3. ventricular tachyarrythmias require ongoing treatment 4 . History evidence clinically significant peripheral vascular disease , intermittent claudication prior amputation 5 . Clinically significant impair renal hepatic function 6 . Stroke within 12 month trial entry . 7 . Known serious allergy fluorescein dye use angiography 8 . Known contraindication component LucentisÂ® formulation . Ocular concomitant conditions/ diseases 1 . Active intraocular inflammation ( grade trace ) either eye 2 . Any active infection ( e.g . conjunctivitis , keratitis , scleritis , uveitis , endophthalmitis ) either eye 3 . History uveitis either eye 4 . Treatment antiangiogenic drug ( pegaptanib sodium , anecortave acetate , bevacizumab , etc . ) intravitreal corticosteroid either eye within 3 month prior inclusion 5 . Angle block glaucoma 6 . Phthisis 7 . Intraocular Pressure &lt; 10mmHg 8 . Macular retinal dystrophy Compliance/ Administrative 1 . Previous participation clinical study investigational drug ( exclude vitamin mineral ) within 1 month ( period correspond 5 halflives investigational drug , whatever long ) prior inclusion . 2 . Patients exclude young 50 year accord definition agerelated AMD . 3 . Women childbearing potential , defined woman physiologically capable become pregnant . 4 . Pregnant nursing ( lactate ) woman 5 . Inability comply study followup procedure . 6 . Any treatment investigational agent past 3 month condition .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>Retinal Function</keyword>
	<keyword>multifocal-ERG</keyword>
	<keyword>Electroretinography</keyword>
	<keyword>microperimetry</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>longterm effect</keyword>
	<keyword>best correct visual acuity</keyword>
	<keyword>BCVA</keyword>
</DOC>